Riskpilot← Back to searchSign inGet full accessStadsApotek Sverige AB
ABActiveOrg 5569126237Trångsundstorget 7Retail sale of pharmaceutical products · NACE 4773Est. 20124 employees
Revenue 2025
SEK 11,6M
+4% vs 2024
EBITDA margin
2.8%
-56% vs 2024
Equity ratio
18.6%
Financial strength
Net profit 2025
SEK 274K
-39% vs 2024
| Revenue | SEK 11,6M | +4% |
| EBITDA | SEK 329K | -56% |
| Net profit | SEK 274K | -39% |
| Total assets | SEK 3M | +0% |
| Equity | SEK 549K | -19% |
| Employees | 4 | — |
Legal name
StadsApotek Sverige AB
Org number
5569126237
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
3 december 2012
Share capital
SEK 50 000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Nouri, Khalid Jabbar
Company purpose
Aktiebolaget ska bedriva försäljning av receptbelagda och receptfria läkemedel samt därmed förenlig verksamhet. Bolaget ska bedriva värdepappershandel samt därmed förenlig verksamhet.
Address
Trångsundstorget 7
Phone
+4687710972
Email
info@trangsundapotek.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 11 212 | 10 815 | 10 471 | 11 095 | 11 563 |
| Staff expenses | — | — | −1 623 | −1 549 | −1 667 |
| EBITDA | 706 | 156 | 392 | 749 | 329 |
| Depreciation & amort. | −60 | −60 | −85 | −53 | −36 |
| EBIT | 646 | 96 | 307 | 697 | 293 |
| Net financials | −1 | −2 | −9 | −25 | −35 |
| Profit before tax | 646 | 95 | 319 | 573 | 351 |
| Tax | −140 | −23 | −72 | −124 | −78 |
| Net profit | 506 | 72 | 247 | 449 | 274 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 2 746 | 2 785 | 2 376 | 2 953 | 2 960 |
| Equity | 1 057 | 680 | 627 | 675 | 549 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 250 | 1 667 | 1 330 | 1 759 | 1 987 |
| Total debt | 1 250 | 1 667 | 1 330 | 1 759 | 1 987 |
EBITDA margin
2.8%
This company
15.8%
Market median
-82% vs market
20212025
Equity ratio
18.6%
This company
38.2%
Market median
-51% vs market
20212025
Return on equity
49.8%
This company
18.4%
Market median
+171% vs market
20212025
Net profit margin
2.4%
This company
8.1%
Market median
-70% vs market
20212025
Asset turnover
3.91×
This company
1.12×
Market median
+249% vs market
20212025
Debt / equity
4.39×
This company
0.62×
Market median
-608% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-05-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
RK Chief Auditor | Chief Auditor | 2025 |
| Former (1) | ||
LJ Audit | Audit | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of StadsApotek Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rimon Khames | Chief Auditor | 0 companies |
| Lars Johan Rudengren | Audit | 0 companies |
| Khalid Jabbar Nouri | Board of Directors | 0 companies |
| Jamila Darwish Ayna Alkalili | Deputy Board Member | 0 companies |